CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
December 2019—NeuMoDx Molecular announced an agreement with Amsterdam-based biotech company Self-screen BV to implement a CE-IVD-marked molecular diagnostic test for high-risk strains of human papillomavirus on the NeuMoDx 288 and NeuMoDx 96 molecular systems.
The HPV assay developed by Self-screen is a real-time PCR-based test that detects 15 high-risk genotypes of human papillomavirus DNA. Under the agreement, Self-screen will handle regulatory processes to obtain the CE-IVD mark while NeuMoDx will manufacture and sell the assay.
Pages: 1 2